Lipitor's Peak Sales Before Generic Entry
Lipitor (atorvastatin), made by Pfizer, hit peak annual sales of $12.9 billion in 2005-2006, accounting for about 10% of Pfizer's total revenue at the time.[1]
When Did Generic Competition Hit and What Was the Immediate Drop?
Lipitor's main U.S. patent expired November 30, 2011, allowing generic atorvastatin to launch December 1. U.S. sales fell 25% in Q4 2011 to $1.5 billion from $2 billion in Q4 2010. Global sales dropped 10% that year to $10.7 billion.[1][2]
Year-Over-Year Revenue Declines Post-Generic Launch
- 2012: Global sales plunged 35% to $7 billion as generics captured 80-90% of U.S. prescriptions within months.[1][2]
- 2013: Further down 30% to $4.9 billion.[2]
- 2014: Dropped another 45% to $2.7 billion, reflecting full generic erosion.[2]
By 2015, sales were under $1 billion annually, a 90%+ decline from peak.[1]
| Year | Global Sales ($B) | YoY Decline |
|------|-------------------|-------------|
| 2011 | 10.7 | 10% |
| 2012 | 7.0 | 35% |
| 2013 | 4.9 | 30% |
| 2014 | 2.7 | 45% |
| 2015 | ~0.8 | ~70% |
Total Revenue Impact on Pfizer
Lipitor generated $125 billion in cumulative sales from 1997-2011. Post-generic peak-to-trough loss exceeded $120 billion in foregone revenue over five years. Pfizer offset this by acquiring smaller drugs, but Lipitor's decline cut company revenue by 20-25% initially.[1][3]
Why the Decline Was So Steep
Generics priced at 80-90% below Lipitor's $4 daily cost launched from Ranbaxy, Watson, Mylan, and others. U.S. market share for branded Lipitor fell from 100% to under 10% by mid-2012, driven by payer formularies favoring cheap alternatives.[2][3] No major patent challenges delayed entry; Lipitor's lipid-lowering patents expired cleanly.[4]
[1]: Pfizer Annual Reports 2005-2015
[2]: FDA Orange Book and Generic Launch Data
[3]: IMS Health (now IQVIA) Sales Reports
[4]: DrugPatentWatch.com - Lipitor Patents